FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to a method of treating and/or preventing obesity and type II diabetes mellitus. Method of treating and/or preventing obesity and type II diabetes mellitus, involving chronic oral administration of a pharmaceutical composition containing 5-pentylresorcinol in dose of 100 mg/kg of 5-pentylresorcinol.
EFFECT: use of the invention provides a high degree of effectiveness in reducing blood glucose and body weight in alimentary obesity and type II diabetes.
1 cl, 11 dwg, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION BASED ON 5-PENTYLRESORCINOL FOR TREATING INFLAMMATORY BOWEL DISEASES | 2023 |
|
RU2829636C1 |
| USE OF 5-PENTADECYLRESORCINOL TO INCREASE PROPORTION OF AKKERMANSIA MUCINIPHILA IN HUMAN MICROBIOME | 2023 |
|
RU2807743C1 |
| PHARMACEUTICAL COMPOSITION INCLUDING A POLYPEPTIDE | 2019 |
|
RU2777095C1 |
| COMPOSITIONS FOR PROPHYLAXIS OR RELIEF OF MULTIPLE RISK FACTOR SYNDROMES | 2001 |
|
RU2291707C2 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| COMPOSITION USED TO COMBAT METABOLIC DISEASES AND USE OF COMPOSITION | 2020 |
|
RU2827553C1 |
| PEPTIDE WITH ANTI-OBESITY AND ANTIDIABETIC EFFICACY AND USE THEREOF | 2017 |
|
RU2721426C1 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| NOVEL FATTY ACID ANALOGS FOR TREATMENT OF DIABETES | 1999 |
|
RU2221558C2 |
| PHARMACEUTICAL COMPOSITION WITH ANTIDIABETIC EFFECT BASED ON OXOVANADIUM DERIVATIVE AND METHOD FOR IT PREPARING | 2001 |
|
RU2203656C1 |
